Artelo biosciences, inc. (ARTL)
CashFlow / Quarterly
Feb'20Nov'19Aug'19May'19Feb'19Nov'18Aug'18May'18Feb'18Nov'17Aug'17May'17Feb'17Nov'16Aug'16May'16Feb'16Nov'15Aug'15May'15Feb'15Nov'14
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net Income (Loss) Attributable to Parent

-1,370,126

-1,306,361

-845,601

-344,883

-424,789

-556,903

-690,113

-577,857

-798,464

-277,057

-115,729

-96,632

-13,011

-9,517

-4,331

-5,050

-5,090

-15,219

-4,591

-2,500

-6,150

-2,000

Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Share-based Payment Arrangement, Noncash Expense

105,397

168,019

49,015

292,740

42,304

41,051

121,253

12,750

138,750

17,251

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

124

124

127

243

70

70

33

103

74

72

-

-

-

-

-

-

-

-

-

-

-

-

Represents the change in fair value for the period of warrant derivative liability.

0

29,501

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase (Decrease) in Operating Capital [Abstract]
Prepaid expenses

11,273

77,797

-18,091

10,338

-28,757

9,462

-20,954

43,915

-2,362

14,785

-

-

-

-

-

-

-

-

-

-

-

-

Other receivable

-16,029

36,800

-

-2,009

5,489

-18,665

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other receivable

-

-

-

-

-

-

-

-

560

767

-

-

-

-

-

-

-

-

-

-

-

-

Increase (Decrease) in Accounts Payable and Accrued Liabilities

-142,616

230,667

-271,880

34,741

-48,697

105,427

39,644

165,307

190,348

105,397

-42,738

68,901

-7,638

-2,889

4,331

1,200

4,709

961

-

-

0

1,500

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-36,669

-22,193

0

0

-3,850

-381

-14,258

-2,852

-4,000

-6,150

-500

Net Cash Provided by (Used in) Operating Activities

-1,402,465

-1,051,649

-1,061,096

-589,454

-740,974

-401,152

-513,872

-458,769

-467,490

-169,889

-

-

-

-

-

-

-

-

-

-

-

-

Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchase of equipment

-

-

-

-

-

-

-42

0

20

867

-

-

-

-

-

-

-

-

-

-

-

-

Net Cash Provided by (Used in) Investing Activities

-

-

-

-

-

-

42

0

-20

-867

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

0

Net Cash Provided by (Used in) Financing Activities [Abstract]
Proceeds from issuance of common stock

-

-

6,700,742

417,732

1,087,131

170,774

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issuance costs

0

15,151

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Represents amount of refund for fractional stock.

0

-117

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collection from stock subscription

-

-

-

-

-

-

-

-

-

10,000

-

-

-

0

0

0

0

600

-

-

-

-

Due to related party

-

-

-

-

-

-

-

-

-

-

-

4,204

0

12,406

-

-

-

0

-

-

-

-

Advance from related party

2,086

4,334

6,054

4,147

4,389

3,686

1,422

1,889

6,632

9,951

21,311

3,174

100

0

0

3,850

0

600

-

-

-

-

Proceeds from (Repayments of) Related Party Debt

0

-3,040

-9,141

-2,866

-4,663

-558

-1,454

-759

-7,338

-8,505

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

253,610

29,500

0

0

3,850

0

1,200

-

-

-

-

Net Cash Provided by (Used in) Financing Activities

2,086

-13,974

6,697,655

419,013

1,086,857

173,902

525,795

269,779

581,431

11,446

-

-

-

-

-

-

-

-

-

-

-

-

Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations

9,419

16,341

967

240

-3,629

4,900

-564

-10,094

-1,254

-1,025

-

-

-

-

-

-

-

-

-

-

-

-

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect

-1,392,136

-1,049,282

-

-

342,254

-222,350

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-

11,401

-199,084

112,667

-160,335

344,280

216,941

7,307

0

0

0

-381

-13,058

4,448

4,500

-6,150

-500

Supplemental Cash Flow Information [Abstract]
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Interest Paid, Excluding Capitalized Interest, Operating Activities

0

0

0

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Income Taxes Paid, Net

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

-

-

0

-

-

-

-

Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Amount of common shares issued for acquisition of license offset against stock payable.

0

539,417

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amount of common shares issued for settlement of stock payable.

0

100,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid during the period for tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

Loan forgiven by previous shareholder

-

-

-

-

-

-

-

-

-

-

-

-

-

16,856

-

-

-

-

-

-

-

-

Share subscription receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0